Carteolol is generally well-tolerated.
Side effects are usually mild and transient.
Nervous system side effects include headache in up to 1% to 17%, asthenia in 8%, insomnia in 5%, dizziness in 8%, paresthesias in 2%, and vertigo, nervousness, headache or fatigue in 1% of patients.
Cardiovascular problems include chest pain in 2% and edema in 1% of patients.
Carteolol may cause or worsen AV heart block.
In the rare cases of new or worsened congestive heart failure that are associated with carteolol, a cause-and-effect relationship is not established.
The etiology of "chest pain" was not described in studies and reviews from the medical literature.
Gastrointestinal complaints of abdominal or epigastric pain in 1% to 7% and diarrhea or nausea in 2% of patients is reported.
Respiratory side effects are rare.
Cough, pharyngitis, or sinusitis are reported in 1% to 5% of patients.
Dyspnea is reported rarely.
Patients with a history of reactive airways disease may be more likely to become short of breath while taking carteolol, as during therapy with any beta-blocker.
Musculoskeletal pain is reported in approximately 3% to 13% of patients.
Carteolol and pindolol, beta-adrenergic receptor antagonists with intrinsic sympathomimetic activity (ISA), have more commonly been associated with muscle cramps and elevated serum creatine phosphokinase (CK) levels than beta-blockers without ISA.
Genitourinary complaints of impotence are reported in less than 1% of male patients.
Psychiatric side effects including reports of depression have been associated with carteolol.